PRAX vs. ETNB, OPK, ARQT, ALXO, SPRY, ABVX, OCUL, IMNM, ZNTL, and TYRA
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include 89bio (ETNB), OPKO Health (OPK), Arcutis Biotherapeutics (ARQT), ALX Oncology (ALXO), ARS Pharmaceuticals (SPRY), ABIVAX Société Anonyme (ABVX), Ocular Therapeutix (OCUL), Immunome (IMNM), Zentalis Pharmaceuticals (ZNTL), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical preparations" industry.
Praxis Precision Medicines (NASDAQ:PRAX) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.
67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 2.8% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Praxis Precision Medicines presently has a consensus target price of $105.80, suggesting a potential upside of 140.45%. 89bio has a consensus target price of $28.14, suggesting a potential upside of 205.90%. Given 89bio's higher probable upside, analysts plainly believe 89bio is more favorable than Praxis Precision Medicines.
89bio received 73 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 62.82% of users gave 89bio an outperform vote while only 62.50% of users gave Praxis Precision Medicines an outperform vote.
Praxis Precision Medicines has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
89bio has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -5,711.85%. 89bio's return on equity of -34.76% beat Praxis Precision Medicines' return on equity.
In the previous week, Praxis Precision Medicines had 1 more articles in the media than 89bio. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 25 mentions for 89bio. Praxis Precision Medicines' average media sentiment score of 0.09 beat 89bio's score of 0.01 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Praxis Precision Medicines has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Summary
89bio beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
